Article

Gene therapy treatment works for inherited blindness

One of the first clinical trial's of a revolutionary gene therapy for Leber's congenital amaurosis (LCA), a type of inherited blindness, showed that the treatment can improve vision and cause no side effects.

London-One of the first clinical trial's of a revolutionary gene therapy for Leber's congenital amaurosis (LCA), a type of inherited blindness, showed that the treatment can improve vision and cause no side effects.

The trial, which was carried out on three patients suffering from LCA caused by an abnormality in gene RPE5, involved inserting healthy copies of the missing RPE65 genes into the cells of the retina to help them function normally. The healthy genes were delivered to the retina using a vector.

The trial began in February 2007 and resulted in one of the patients benefiting from significantly improved night vision. He was able to negotiate a simulation of a night-time scene quickly and without mistakes, which he could not have done before the surgery.

"Showing for the first time that gene therapy can work in patients with eye disease is a very significant milestone," said Robin Ali, PhD, University College London, Institute of Ophthalmology who led the trial. "This trial paves the way for the development of gene therapy approaches for a broad range of eye disorders."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.